Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 112 resultater
Tid
Selskap
Tittel
Sektor
Kategori
16 Oct 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Publication of ESMO Congress 2023 Abstract on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma
20103010 Biotechnology
Other subject
16 Oct 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA PUBLICATION D'UN ABSTRACT AU CONGRÈS DE L’ESMO 2023 SUR L'ESSAI DE PHASE 1/2 EN COURS DANS LE GLIOBLASTOME, NOX-A12 GLORIA
20103010 Biotechnology
Other subject
10 Oct 2023
08:00 CEST
TME PHARMA
TME PHARMA PRESENTE UNE MISE À JOUR POSITIVE DES DONNÉES DE SURVIE À 18 MOIS DU TRAITEMENT PAR NOX-A12 EN COMBINAISON DANS LE CANCER DU CERVEAU ET ANNONCE SA DÉCISION DE SOLLICITER LA FDA AMÉRICAINE
20103010 Biotechnology
Other subject
10 Oct 2023
08:00 CEST
TME PHARMA
TME Pharma Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer and Provides Strategic Update Including Decision to Engage with US FDA
20103010 Biotechnology
Other subject
22 Sep 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting
20103010 Biotechnology
Other subject
22 Sep 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE QUE DEUX ABSTRACTS CLINIQUES SUR L'ESSAI DE PHASE 1/2 GLORIA EN COURS ÉVALUANT NOX-A12 DANS LE GLIOBLASTOME FERONT L’OBJET D’UNE PRÉSENTATION AU CONGRÈS DE L’ESMO 2023 ET À LA RÉUNION ANNUELLE SNO 2023
20103010 Biotechnology
Other subject
13 Sep 2023
08:00 CEST
TME PHARMA
L’ASSOCIATION DE NOX-A12 AVEC BEVACIZUMAB PRESENTE UN TAUX DE SURVIE À 17 MOIS DÉPASSANT CELUI DE TOUS LES TRAITEMENTS CONCURRENTS PERTINENTS CONTRE LA FORME LA PLUS GRAVE DE CANCER DU CERVEAU CHEZ L'ADULTE
20103010 Biotechnology
Other subject
13 Sep 2023
08:00 CEST
TME PHARMA
TME Pharma N.V. : NOX-A12 Combination Regimen With Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer
20103010 Biotechnology
Other subject
20 Jul 2023
18:00 CEST
TME PHARMA
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
20103010 Biotechnology
Share history
20 Jul 2023
18:00 CEST
TME PHARMA
TME Pharma N.V. : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC INVEST SECURITIES
20103010 Biotechnology
Share history
13 Jul 2023
08:00 CEST
TME PHARMA
TME PHARMA PRÉSENTE DES DONNÉES POSITIVES SUR LA MEILLEURE RÉPONSE AU TRAITEMENT AVEC UNE PREMIÈRE RÉPONSE COMPLÈTE DANS L'ÉTUDE GLORIA SUR LE GLIOBLASTOME, CE QUI PORTE À 50 % DE PATIENTS DU BRAS D’EXPANSION AYANT OBTENU UNE RÉPONSE COMPLÈTE OU...
20103010 Biotechnology
Other subject
13 Jul 2023
08:00 CEST
TME PHARMA
TME Pharma Provides Positive Data Update on Best Response to Therapy With First Complete Response in GLORIA Trial in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near-Complete Response
20103010 Biotechnology
Other subject
28 Jun 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
20103010 Biotechnology
Other subject
28 Jun 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LES RESULTATS POSITIFS DE SURVIE A 15 MOIS DU BRAS D'EXPANSION DE L’ETUDE GLORIA EVALUANT LE NOX-A12 EN COMBINAISON AVEC LA RADIOTHERAPIE ET LE BEVACIZUMAB DANS LE GLIOBLASTOME
20103010 Biotechnology
Other subject
15 Jun 2023
18:00 CEST
TME PHARMA
TME Pharma Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA
20103010 Biotechnology
Other subject
15 Jun 2023
18:00 CEST
TME PHARMA
TME PHARMA REÇOIT L'APPROBATION DE LA FDA AMÉRICAINE POUR LE LANCEMENT D’UN NOUVEL ESSAI CLINIQUE (IND) EVALUANT NOX-A12 AUX ETATS-UNIS
20103010 Biotechnology
Other subject
30 May 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders
20103010 Biotechnology
General meeting / Board Meeting
30 May 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA CONVOCATION DE L’ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES 2023
20103010 Biotechnology
General meeting / Board Meeting
26 May 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Publication of ASCO 2023 Abstract Disclosing New Biomarker Data From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma
20103010 Biotechnology
New
26 May 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA PUBLICATION D'UN ABSTRACT ASCO 2023 PRÉSENTANT DE NOUVELLES DONNÉES SUR LES BIOMARQUEURS ISSUES DE L'ESSAI DE PHASE 1/2 NOX-A12 GLORIA DANS LE GLIOBLASTOME
20103010 Biotechnology
New
25 May 2023
18:00 CEST
TME PHARMA
TME PHARMA PRESENTE DES DONNEES DE SURVIE POSITIVES A 14 MOIS DU BRAS D'EXPANSION GLORIA EVALUANT LE NOX-A12 EN COMBINAISON AVEC LA RADIOTHERAPIE ET LE BEVACIZUMAB DANS LE GLIOBLASTOME
20103010 Biotechnology
Other subject
25 May 2023
18:00 CEST
TME PHARMA
TME Pharma Provides Positive Clinical Update and 14-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
20103010 Biotechnology
Other subject
27 Apr 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA PRÉSENTATION DES DONNÉES DE PHASE 1/2 DE NOX-A12 DANS LE GLIOBLASTOME LORS DE LA RÉUNION ANNUELLE DE L’ASCO EN JUIN 2023
20103010 Biotechnology
Other subject
27 Apr 2023
08:00 CEST
TME PHARMA
TME Pharma Announces New Data From NOX-A12 GLORIA Phase 1/2 Study in Glioblastoma to Be Presented at ASCO Annual Meeting in June 2023
20103010 Biotechnology
Other subject
25 Apr 2023
00:51 CEST
TME PHARMA
CORRIGE ET REMPLACE : TME PHARMA PUBLIE SON RAPPORT ANNUEL AUDITÉ POUR L’ANNÉE 2022
20103010 Biotechnology
Other subject
25 Apr 2023
00:51 CEST
TME PHARMA
CORRECTING and REPLACING: TME Pharma Publishes Audited Annual Report 2022
20103010 Biotechnology
Other subject
24 Apr 2023
18:00 CEST
TME PHARMA
TME Pharma Publishes Audited Annual Report 2022
20103010 Biotechnology
Income
24 Apr 2023
18:00 CEST
TME PHARMA
TME PHARMA PUBLIE SON RAPPORT ANNUEL AUDITÉ POUR L’ANNÉE 2022
20103010 Biotechnology
Income
18 Apr 2023
20:00 CEST
TME PHARMA
TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program With a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway Into December 2023
20103010 Biotechnology
Other subject
18 Apr 2023
20:00 CEST
TME PHARMA
TME PHARMA ANNONCE LE SUCCÈS D'UN FINANCEMENT DE 2 MILLIONS D'EUROS ET LA FIN DU PROGRAMME D'OBLIGATIONS CONVERTIBLES AVEC BLOCAGE DES ACTIONS NOUVELLES ET BLOCAGE DES CONVERSIONS D'OBLIGATIONS PROLONGEANT SA VISIBILITE FINANCIÈRE...
20103010 Biotechnology
Other subject
18 Apr 2023
18:00 CEST
TME PHARMA
TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022
20103010 Biotechnology
Income
18 Apr 2023
18:00 CEST
TME PHARMA
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS 2022 NON AUDITÉS
20103010 Biotechnology
Income
29 Mar 2023
08:50 CEST
TME PHARMA
TME Pharma Announces Temporary Suspension of Liquidity Contract With Invest Securities
20103010 Biotechnology
Other subject
29 Mar 2023
08:50 CEST
TME PHARMA
TME PHARMA ANNONCE LA SUSPENSION TEMPORAIRE DE SON CONTRAT DE LIQUIDITÉ AVEC INVEST SECURITIES
20103010 Biotechnology
Other subject
27 Mar 2023
08:00 CEST
TME PHARMA
TME Pharma Announces 83% of Glioblastoma Patients Still Alive After 12 Months on Study (Median) in GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab
20103010 Biotechnology
Other subject
27 Mar 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE QUE 83% DES PATIENTS ATTEINTS DE GLIOBLASTOME SONT TOUJOURS EN VIE APRÈS 12 MOIS D'ÉTUDE (MÉDIANE) DANS LE BRAS D'EXPANSION GLORIA ÉVALUANT LE NOX-A12 EN COMBINAISON AVEC LA RADIOTHÉRAPIE ET LE BEVACIZUMAB
20103010 Biotechnology
Other subject
24 Feb 2023
08:00 CET
TME PHARMA
MESSAGE DU PDG DE TME PHARMA
20103010 Biotechnology
Other subject
24 Feb 2023
08:00 CET
TME PHARMA
TME Pharma CEO Message
20103010 Biotechnology
Other subject
30 Jan 2023
18:00 CET
TME PHARMA
TME PHARMA ANNONCE LE RÉSULTAT DE L'ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DES ACTIONNAIRES
20103010 Biotechnology
General meeting / Board Meeting
30 Jan 2023
18:00 CET
TME PHARMA
TME Pharma Announces Results of the Extraordinary General Meeting of Shareholders
20103010 Biotechnology
General meeting / Board Meeting
23 Jan 2023
08:00 CET
TME PHARMA
TME PHARMA PRÉSENTE UNE MISE A JOUR CLINIQUE SUR LE BRAS D'EXPANSION GLORIA TESTANT NOX-A12 EN COMBINAISON AVEC LA RADIOTHERAPIE ET LE BEVACIZUMAB CHEZ LES PATIENTS ATTEINTS DE GLIOBLASTOME
-
New
23 Jan 2023
08:00 CET
TME PHARMA
TME Pharma Provides Clinical Update on the Gloria Expansion Arm Testing NOX-A12 in Combination With Radiotherapy and Bevacizumab in Patients With Glioblastoma
-
New
20 Jan 2023
18:00 CET
TME PHARMA
TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities
20103010 Biotechnology
Share history
20 Jan 2023
18:00 CET
TME PHARMA
TME PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC INVEST SECURITIES
20103010 Biotechnology
Share history
30 Dec 2022
18:00 CET
TME PHARMA
TME Pharma Announces Convocation of an Extraordinary General Meeting of Shareholders
20103010 Biotechnology
General meeting / Board Meeting
30 Dec 2022
18:00 CET
TME PHARMA
TME PHARMA ANNONCE LA CONVOCATION D’UNE ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DES ACTIONNAIRES
20103010 Biotechnology
General meeting / Board Meeting
28 Nov 2022
18:00 CET
TME PHARMA
TME Pharma Announces the Resignation of Its Chief Financial Officer Bryan Jennings
20103010 Biotechnology
Corporate life
28 Nov 2022
18:00 CET
TME PHARMA
TME PHARMA ANNONCE LA DEMISSION DE SON DIRECTEUR FINANCIER BRYAN JENNINGS
20103010 Biotechnology
Corporate life
19 Nov 2022
01:30 CET
TME PHARMA
Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in Brain Cancer Presented at the Society for Neuro-oncology 2022 Annual Meeting
20103010 Biotechnology
Other subject
19 Nov 2022
01:30 CET
TME PHARMA
PRESENTATION DES RÉSULTATS INTERMÉDIAIRES POSITIFS ACTUALISES DE LA PHASE 1/2 DE NOX-A12 GLORIA DANS LE CANCER DU CERVEAU A L’OCCASION DE LA RÉUNION ANNUELLE 2022 DE LA SOCIETY FOR NEURO-ONCOLOGY (SNO)
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva